预防埃博拉病毒病的疫苗。
Vaccines for preventing Ebola virus disease.
机构信息
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Department of Clinical Pharmacology, Royal Liverpool University Hospital, Liverpool, UK.
出版信息
Cochrane Database Syst Rev. 2024 Nov 19;11(11):CD015828. doi: 10.1002/14651858.CD015828.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of vaccines to prevent Ebola virus disease in people who have been, or have potentially been, exposed to Ebola virus.
摘要
这是一篇 Cochrane 综述（干预措施）的方案。其目的如下：评估针对已接触或可能接触埃博拉病毒的人群的疫苗预防埃博拉病毒病的效果。
相似文献
1
Vaccines for preventing Ebola virus disease.
Cochrane Database Syst Rev. 2024 Nov 19;11(11):CD015828. doi: 10.1002/14651858.CD015828.
2
Current Ebola Virus Vaccine Progress.
BioDrugs. 2019 Feb;33(1):9-14. doi: 10.1007/s40259-018-0329-7.
3
[Overview of the Ebola vaccines in pre-clinical and clinical development].
Bull Soc Pathol Exot. 2016 Oct;109(4):256-261. doi: 10.1007/s13149-016-0521-2. Epub 2016 Sep 19.
4
Development of vaccines for prevention of Ebola virus infection.
Microbes Infect. 2015 Feb;17(2):98-108. doi: 10.1016/j.micinf.2014.12.004. Epub 2014 Dec 16.
5
Immunology of protection from Ebola virus infection.
Sci Transl Med. 2015 May 6;7(286):286ps11. doi: 10.1126/scitranslmed.aaa8202.
6
Vaccine trial launched to stop Ebola.
Science. 2018 May 18;360(6390):694-695. doi: 10.1126/science.360.6390.694.
7
Ebola in eastern DRC.
Lancet Infect Dis. 2019 Oct;19(10):1049-1050. doi: 10.1016/S1473-3099(19)30422-0. Epub 2019 Aug 8.
8
A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721). doi: 10.1098/rstb.2016.0295.
9
Ebola vaccine candidates are tested in humans.
Hum Vaccin Immunother. 2014;10(11):3103. doi: 10.4161/21645515.2014.995038.
10
Basic science and the Ebola virus infection epidemic.
Pharmacotherapy. 2014 Nov;34(11):1115-7. doi: 10.1002/phar.1520.
本文引用的文献
1
Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo.
Lancet Infect Dis. 2024 Jun;24(6):602-610. doi: 10.1016/S1473-3099(23)00819-8. Epub 2024 Feb 7.
2
Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis.
Lancet Microbe. 2022 Sep;3(9):e683-e692. doi: 10.1016/S2666-5247(22)00123-9. Epub 2022 Jul 5.
3
Current state of Ebola virus vaccines: A snapshot.
PLoS Pathog. 2021 Dec 9;17(12):e1010078. doi: 10.1371/journal.ppat.1010078. eCollection 2021 Dec.
4
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
J Clin Epidemiol. 2021 Jun;134:178-189. doi: 10.1016/j.jclinepi.2021.03.001. Epub 2021 Mar 29.
5
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline.
BMJ. 2020 Jan 16;368:l6890. doi: 10.1136/bmj.l6890.
6
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
7
RoB 2: a revised tool for assessing risk of bias in randomised trials.
BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.
8
Ebola virus disease.
Lancet. 2019 Mar 2;393(10174):936-948. doi: 10.1016/S0140-6736(18)33132-5. Epub 2019 Feb 15.
9
Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies.
Front Immunol. 2018 May 9;9:1025. doi: 10.3389/fimmu.2018.01025. eCollection 2018.
10
Evidence-based guidelines for supportive care of patients with Ebola virus disease.
Lancet. 2018 Feb 17;391(10121):700-708. doi: 10.1016/S0140-6736(17)31795-6. Epub 2017 Oct 17.
Zotero 插件